Provence Technologies and Neuroptis Biotech partner to develop a new compound for treating dry eye syndrome

22-May-2012 - France

Provence Technologies announced the further strengthening of their collaboration for transferring the chemical development of Neuroptis Biotech’s drug candidate, ML7, and producing the first GMP batches before the end of 2012.

ML7 is a drug candidate for the treatment of dry eye syndromes. It is the first of a new therapeutic class and has the potential to provide a targeted and effective therapeutic remedy for the millions of people suffering from dry eye syndrome, Gougerot-Sjogren syndrome and inflammations, especially ones caused by allergies.

Provence Technologies and Neuroptis Biotech have already collaborated successfully in developing a synthetic pathway for ML7, manufacturing the first non-GMP batches and devising associated analytical methods. The two companies have embarked on the process optimization phase to facilitate the transfer of the compound and the start of production on an industrial scale, scheduled for September this year.

https://www.bionity.com/en/news/138024/provence-technologies-and-neuroptis-biotech-partner-to-develop-a-new-compound-for-treating-dry-eye-syndrome.html